FISHERS, Ind., Dec. 2, 2011 /PRNewswire/ -- Positron
Corporation (OTCBB: POSC), a leading molecular imaging company
specializing in the field of nuclear cardiology, is pleased to
announce that Amerinet has awarded a Group Purchasing Agreement for
their PosiRx system to begin January 1,
2012 for a three-year period.
Amerinet is a Group Purchasing Organization (GPO), which enters
into arrangements for the purchase of products and services on
behalf of its member facilities. Amerinet provides a broad
portfolio of agreements, products and services capable of serving
healthcare organizations, both hospitals and non-hospitals alike.
Amerinet's objective is to secure new opportunities with emerging
technology vendors in order to reduce costs and improve
efficiencies to its member network.
Positron's objective is to offer the PosiRx System throughout
Amerinet's network of over 50,000 members. Positron's PosiRx
technology will meet the needs of those Amerinet members desiring
efficient radiopharmaceutical solutions for their cardiac SPECT
pharmacy needs.
"We believe the PosiRx system will impact and redefine the
industry by offering a more efficient and economical alternative to
the current nuclear pharmacy model. We are excited to work
with Amerinet and their extensive member network, as our innovative
solutions are well-aligned with their vision," stated Michael Stewart, Positron's Director of
Radiopharmaceutical Business Development.
PosiRx is a radiopharmaceutical system that automates the
elution, preparation and dispensing processes for
radiopharmaceutical agents used in molecular imaging. It was
created to simplify and control the procedures associated with
compounding radiopharmaceuticals. PosiRx is the first system
of its kind to offer a complete and comprehensive automated
solution in nuclear medicine.
About Positron: Positron Corporation is a leading
molecular imaging company providing innovative nuclear medicine
technologies and services that are reshaping the field of nuclear
cardiology. Through proprietary PET imaging systems and
radiopharmaceutical solutions, Positron enables healthcare
providers to more accurately diagnose disease and improve patient
outcomes while practicing cost effective medicine. Positron
has gained significant traction in a diverse industry and continues
their strong commitment to excellence and advancing cardiac imaging
solutions. More information about Positron is available at
www.positron.com.
About Amerinet: As a leading national healthcare
solutions organization, Amerinet collaborates with acute and
non-acute care providers to create and deliver unique solutions
through performance improvement resources, guidance and ongoing
support. With better product standardization and utilization, new
financial tools beyond contracting and alliances that help lower
costs, raise revenue and champion quality, Amerinet enriches
healthcare delivery for its members and the communities they serve.
To learn more about how Amerinet can help you successfully navigate
the future of healthcare reform, visit www.amerinet-gpo.com.
Forward Looking Statements: Statements in this document
contain certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements are
based on many assumptions and estimates and are not guarantees of
future performance. These statements may involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Positron Corporation to be
materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. Positron assumes no obligation to publicly update or
revise these forward-looking statements for any reason, or to
update the reasons actual results could differ materially from
those anticipated in these forward-looking statements, even if new
information becomes available in the future. Our actual
results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including,
without limitation those set forth as "Risk Factors" in our filings
with the Securities and Exchange Commission.
SOURCE Positron Corporation